Very Early Transition to Oral Antibiotics in Uncomplicated Enterobacterales Bloodstream Infections: Effectiveness and Impact on Carbon Footprint Saving

<b>Background/Objective</b>: This study aimed to evaluate the effectiveness of very early oral transition in Enterobacterales bloodstream infections (E-BSIs), identify factors associated with it, compare the effectiveness of different oral options, and assess its economic and ecological benefits. <b>Methods</b>: Retrospective, observational cohort study including monomicrobial E-BSI in clinically stable adult patients by day 3 of bacteremia with oral antibiotic options. Transition to oral antibiotics by day 3 or earlier (early oral (EO) group) was compared to later transition or remaining on intravenous therapy (nEO group). Early oral transition-associated factors were analyzed. Oral high-dose beta-lactams (BLs) were compared to quinolones (QLs) or trimethoprim/sulfamethoxazole (TS). Economic and ecological costs were assessed. <b>Results</b>: Of 345 E-BSI, 163 (47.2%) were in the EO group, characterized by more urinary tract infections (UTIs) and shorter hospital stays. The nEO group had higher Charlson Comorbidity Index (CCI), extended-spectrum beta-lactamase (ESBL) production, greater source control need, and longer time to clinical stability. There were no significant differences in mortality and relapse. UTIs were associated with early oral transition (OR 2.02, IC 95% 1.18-3.48), while higher CCI (0.85, 0.77-0.95), source control need (0.39, 0.19-0.85), longer time to clinical stability (0.51, 0.39-0.66), and ESBL isolates (0.39, 0.19-0.80) hindered this practice. High-dose BLs and QL/TS were equally effective. Early oral transition resulted in 38.794 KgCO<sub>2</sub>eq reduction and EUR 269,557.99 savings. <b>Conclusions</b>: Very early oral transition at day 3 or before in stable E-BSI patients is effective, eco-sustainable, and cost-effective; UTI is related with the early oral switch, while comorbidities, ESBL production, source control need, or longer time to clinical stability hinder this practice.

Authors

Institutions

Publication Details

Journal
Antibiotics
Published
2025-07-25
DOI
https://doi.org/10.3390/antibiotics14080751
Citations
1
Primary Topic
Urinary Tract Infections Management
Type
article
Field-Weighted Citation Impact
1.35

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Very Early Transition to Oral Antibiotics in Uncomplicated Enterobacterales Bloodstream Infections: Effectiveness and Impact on Carbon Footprint Saving

María López-Sánchez, Mariona Xercavins, Esther Calbo, Clara Gallego et al.
1 citations
Antibiotics
Urinary Tract Infections Management
1.35
article

Very Early Transition to Oral Antibiotics in Uncomplicated Enterobacterales Bloodstream Infections: Effectiveness and Impact on Carbon Footprint Saving

María López-Sánchez, Mariona Xercavins, Esther Calbo, Clara Gallego, Silvia Álvarez-Torrellas, Beatriz Dietl, Laura Gisbert, Ana Martínez-Urrea, Josefa Pérez, S. Rodríguez, Aina Mateu, Lucía Boix-Palop, Toni Roselló
article en
1 citations

Abstract

<b>Background/Objective</b>: This study aimed to evaluate the effectiveness of very early oral transition in Enterobacterales bloodstream infections (E-BSIs), identify factors associated with it, compare the effectiveness of different oral options, and assess its economic and ecological benefits. <b>Methods</b>: Retrospective, observational cohort study including monomicrobial E-BSI in clinically stable adult patients by day 3 of bacteremia with oral antibiotic options. Transition to oral antibiotics by day 3 or earlier (early oral (EO) group) was compared to later transition or remaining on intravenous therapy (nEO group). Early oral transition-associated factors were analyzed. Oral high-dose beta-lactams (BLs) were compared to quinolones (QLs) or trimethoprim/sulfamethoxazole (TS). Economic and ecological costs were assessed. <b>Results</b>: Of 345 E-BSI, 163 (47.2%) were in the EO group, characterized by more urinary tract infections (UTIs) and shorter hospital stays. The nEO group had higher Charlson Comorbidity Index (CCI), extended-spectrum beta-lactamase (ESBL) production, greater source control need, and longer time to clinical stability. There were no significant differences in mortality and relapse. UTIs were associated with early oral transition (OR 2.02, IC 95% 1.18-3.48), while higher CCI (0.85, 0.77-0.95), source control need (0.39, 0.19-0.85), longer time to clinical stability (0.51, 0.39-0.66), and ESBL isolates (0.39, 0.19-0.80) hindered this practice. High-dose BLs and QL/TS were equally effective. Early oral transition resulted in 38.794 KgCO<sub>2</sub>eq reduction and EUR 269,557.99 savings. <b>Conclusions</b>: Very early oral transition at day 3 or before in stable E-BSI patients is effective, eco-sustainable, and cost-effective; UTI is related with the early oral switch, while comorbidities, ESBL production, source control need, or longer time to clinical stability hinder this practice.

AntibioticsVol. 14(8)
Universitat Internacional de Catalunya (ES), University Hospital Mútua de Terrassa (ES), Hospital de Viladecans (ES), Mútua Terrassa (ES)
European Society of Clinical Microbiology and Infectious Diseases
Openalex Percentile: Top 17%
Urinary Tract Infections Management
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.